Page 208 - HIV/AIDS Guidelines

Table 15d. Drug Interactions between CCR5 Antagonist and Other Drugs

This table provides information relating to PK interactions between MVC and non-ARV drugs. For interactions among ARV
agents and for dosing recommendations, please refer to Table 16b.

Effect on CCR5
Concomitant Drug CCR5 Antagonist or Dosing Recommendations and Clinical Comments
Class/Name Antagonist Concomitant Drug
Concentrations
Anticonvulsants

Carbamazepine MVC ↓ MVC possible If used without a strong CYP3A inhibitor, use MVC 600 mg BID or
Phenobarbital an alternative antiepileptic agent.
Phenytoin

Antifungals
Itraconazole MVC ↑ MVC possible Dose: MVC 150 mg BID

Ketoconazole MVC MVC AUC ↑ 400% Dose: MVC 150 mg BID
Voriconazole MVC ↑ MVC possible Consider dose reduction to MVC 150 mg BID
Antimycobacterials

Clarithromycin MVC ↑ MVC possible Dose: MVC 150 mg BID
Rifabutin MVC ↓ MVC possible If used without a strong CYP3A inducer or inhibitor, use
MVC 300 mg BID.
If used with a strong CYP3A inhibitor, use MVC 150 mg BID.
Rifampin MVC MVC AUC ↓ 64% Coadministration is not recommended.
If coadministration is necessary, use MVC 600 mg BID.
If coadministered with a strong CYP3A inhibitor, use
MVC 300 mg BID.

Rifapentine MVC ↓ MVC expected Do not coadminister.
Herbal Products
St. John’s wort MVC ↓ MVC possible Coadministration is not recommended.

Hormonal Contraceptives
Hormonal MVC No significant effect on Safe to use in combination
contraceptives ethinyl estradiol or
levonorgestrel
Narcotics/Treatment for Opioid Dependence

Methadone MVC No data

Key to Abbreviations: ARV = antiretroviral, AUC = area under the curve, BID = twice daily, CYP = cytochrome P, MVC = maraviroc,
PK = pharmacokinetic

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents K-38

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.